Chargement en cours...
The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by (89)Zr-immuno-PET in xenograft bearing mice
Probody(®) therapeutics are recombinant masked monoclonal antibody (mAb) prodrugs that become activated by proteases present in the tumor microenvironment. This makes them attractive for use as Probody drug conjugates (PDCs). CX-2009 is a novel PDC with the toxic drug DM4 coupled to an anti-CD166 Pr...
Enregistré dans:
| Publié dans: | Theranostics |
|---|---|
| Auteurs principaux: | , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Ivyspring International Publisher
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7255005/ https://ncbi.nlm.nih.gov/pubmed/32483421 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.44334 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|